Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis by Pezzilli, Raffaele et al.
Case Rep Gastroenterol 2011;5:378–385 
DOI: 10.1159/000330291 
Published online: 
July 9, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–0631 
www.karger.com/crg   
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online
version of the article only. Distribution for non-commercial purposes only. 
 
 
Raffaele Pezzilli    Pancreas Unit, Department of Digestive Diseases and Internal Medicine 
Sant’Orsola-Malpighi Hospital, IT–40138 Bologna (Italy) 
Tel. +39 051 636 4148, E-Mail raffaele.pezzilli @ aosp.bo.it 
 
378
   
Pancreatic Ductal 
Adenocarcinoma Associated 
with Autoimmune Pancreatitis 
Raffaele Pezzillia    Silvia Vecchiarellib    Maria Cristina Di Marcob    
Carla Serraa    Donatella Santinic    Lucia Calcullid    Dario Fabbria    
Betzabè Rojas Menae    Andrea Imbrognoa 
aPancreas Unit, Department of Digestive Diseases and Internal Medicine, and 
Departments of bOncology, cPathology and dRadiology, Sant’Orsola-Malpighi 
Hospital, University of Bologna, Bologna, Italy; eDepartment of Pathology, 
Rafael Ángel Calderón Guardia Hospital, San José, Costa Rica 
 
 
Key Words 
Autoimmune pancreatitis · Pancreatitis · Pancreatic neoplasms · Therapy · Outcome · 
Azathioprine · Pathology 
Abstract 
Autoimmune pancreatitis (AIP), in contrast to other benign chronic pancreatic diseases, 
can be cured with immunosuppressant drugs, thus the differentiation of AIP from 
pancreatic cancer is of particular interest in clinical practice. There is the possibility that 
some patients with AIP may develop pancreatic cancer, and this possibility contributes 
to increasing our difficulties in differentiating AIP from pancreatic cancer. We herein 
report the case of a 70-year-old man in whom pancreatic adenocarcinoma and AIP were 
detected simultaneously. We must carefully monitor AIP patients for the simultaneous 
presence of pancreatic cancer, even when a diagnosis of AIP is confirmed. 
Introduction 
Pancreatitis due to autoimmunity has not only been reported in Japan; in the last 
decade, the frequency of new diagnoses has increased all over the world [1, 2]. An 
autoimmune pathogenesis for this disease has been proposed because this condition 
is occasionally associated with antibodies or other autoimmune-associated diseases  
[3–9]. The terms type 1 and type 2 autoimmune pancreatitis (AIP) have recently been 
introduced to describe the clinical profiles associated with lymphoplasmacytic sclerosing 
pancreatitis and idiopathic duct-centric pancreatitis [10]. The two entities share common 
histopathologic features, even if expert pathologists can accurately distinguish them on Case Rep Gastroenterol 2011;5:378–385 
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the basis of other unique histopathologic characteristics. In a clinical setting, both 
type 1 and type 2 AIP have a similar presentation, and they are characterized by 
obstructive jaundice, a pancreatic mass and a dramatic response to steroids, but differ 
in demography, serology, involvement of other organs and disease relapse rate. While 
type 1 is associated with elevation of nonspecific autoantibodies and serum IgG4 levels 
[11], type 2 does not have definitive serologic autoimmune markers. In addition, high 
serum IgG4 may also be found in patients with pancreatic cancer [11], and serum 
neoplastic markers such as CA19-9, SPAN-1 and DUPAN-2 may also be elevated in 
patients with AIP [12]; these findings sometimes render the diagnosis of AIP confusing. 
Since AIP, in contrast to other benign chronic pancreatic diseases, can be cured with 
immunosuppressant drugs [13], the differentiation of AIP from pancreatic cancer is of 
particular interest in clinical practice [14]. Two studies have also pointed out the 
possibility that some patients with AIP may develop pancreatic cancer [15, 16], and this 
contributes to increasing our difficulties in differentiating AIP from pancreatic cancer. 
We herein report the case of a patient in whom pancreatic adenocarcinoma and AIP were 
detected simultaneously. 
Case Report 
A 70-year-old man was admitted to our hospital in June 2010 for additional examination and 
suitable treatment for suspected pancreatic cancer. The patient was a light drinker (daily pure alcohol 
intake <40 g) and did not smoke. He had a history of HCV-related hepatitis which had been 
unsuccessfully treated with IFN; treatment had been discontinued due to serious depression. Familial 
history was negative for the presence of pancreatic and extrapancreatic cancer. 
In April 2010, he became jaundiced and was admitted to another hospital. No other clinical 
symptoms were present. He underwent an abdominal computed tomography (CT) scan showing a mass 
in the pancreatic head measuring 5 × 3.5 cm, infiltrating the left gastric artery with compression and 
displacement of the portal vein; dilation of the common bile duct was also seen. Endoscopic retrograde 
pancreatography revealed severe narrowing of the duodenal lumen suggestive of infiltrating ductal 
adenocarcinoma; a duodenal biopsy showed flogistic tissue without signs of invasive neoplasia. An 
explorative laparotomy was performed in May 2010 and, during surgery, a bulky lesion in the head of 
the pancreas with vascular involvement was detected. Since the lesion caused massive infiltration of the 
duodenal wall and due to the close proximity of the mass to the inferior cava vein, hepatic artery and 
portal vein, a double bypass biliary-enteric and gastro-enteric bypass was performed. During surgery, a 
peritoneal biopsy was also performed because of the presence of small nodules on the peritoneal surface, 
but no signs of cancer were detected histologically, and cytological examination of the peritoneal lavage 
was also negative for the presence of malignant cells. A CT scan carried out in the postoperative period 
confirmed the pancreatic mass without dilation of the Wirsung duct (fig. 1); cytology of the pancreatic 
mass was carried out and no malignant cells were detected. 
The patient was finally sent to our Unit in July 2010 for further investigation. On admission, 
performance status was good; he did not complain of abdominal pain and his body weight had 
increased after surgery. The results of the following blood chemistry examinations were abnormal: 
serum amylase 211 U/l (upper reference value 110 U/l), lipase 155 U/l (upper reference value 60 U/l), 
and alkaline phosphatases 333 U/l (normal reference range 98–280 U/l); γ-glutamyltranspeptidase 
39 U/l (normal reference range 8–61 U/l) and glucose 103 mg/dl were within the normal reference 
ranges. The serum levels of CA19-9 and CEA were 1,128 U/ml (normal reference range 0–37 U/ml) and 
4.5 ng/ml (normal reference range 0–5 ng/ml), respectively; IgG4 was 19 mg/dl (normal reference range 
8–140 mg/dl). He underwent ultrasound-guided fine needle biopsy which disclosed chronic pancreatitis 
with lymphoplasmacytic infiltrate, a low number of eosinophils and intralobular and interlobular 
fibrosis, associated with granulocytic epithelial lesions and panIN 1A–B (fig. 2) suggestive of a diagnosis 
of AIP. Moreover, 18-fluorodeoxyglucose positron emission tomography (18 FDG-PET) showed a 
markedly increased glucose uptake in the head of the pancreas (SUV 6.1) and was unremarkable for 
differentiating pancreatic cancer from AIP (fig. 3). Case Rep Gastroenterol 2011;5:378–385 
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In August 2010, the patient was treated with azathioprine at a dosage of 100 mg/day and not 
with steroids because of the presence of viral hepatitis; two months later, his clinical condition 
remained good. However, the serum levels of the tumor markers continued to increase (CA19-9 
>10,000 U/ml, CEA 39.5 ng/ml) and diabetes was diagnosed requiring metformin and insulin 
treatment. Another CT scan was carried out in October 2010, and this examination showed that 
the pancreatic mass had increased in volume (6 × 5.7 cm) and the main pancreatic duct was dilated 
behind the solid mass (fig. 4). Multiple hepatic lesions of a few millimeters, hyperdense in the arterial 
and the delayed phase, were also detected. The patient underwent another ultrasound-guided fine 
needle biopsy which showed the presence of intense fibrosis due to immunosuppressive therapy, the 
presence of a poor lymphoplasmacytic infiltrate and an intraductal papillary mucinous tumor; a ductal 
adenocarcinoma was also found (fig. 5). Azathioprine was discontinued and the patient underwent 
chemotherapy based on gemcitabine and oxaliplatin for 3 months and then on gemcitabine associated 
with capecitabine. After 8 months, the patient is still alive and continuing his chemotherapy. 
Discussion 
Several hypotheses can be advanced regarding the possible relationship between 
pancreatic adenocarcinoma and AIP. It is possible that AIP can induce a carcinoma 
or, on the contrary, an adenocarcinoma may induce an inflammatory process mimicking 
that of AIP. The synchronous presence of adenocarcinoma and AIP cannot be excluded. 
All these hypotheses are supported by the data in the literature. In fact, it is possible 
that the obstruction of the pancreatic duct by the tumoral mass may determine an 
inflammatory process resembling that of AIP [17]. However, the localization of the 
ductal adenocarcinoma in the central part of the mass as in the present case and in the 
case reported by Motosugi et al. [17] is highly supportive of the hypothesis that AIP 
precedes adenocarcinoma formation. This also agrees with previous studies showing 
that pancreatic carcinoma develops several months or years after the diagnosis of AIP 
[15, 16, 18–20] and that patients with AIP may have a K-ras mutation [21]. At present, 
we cannot answer the question regarding the synchronous [17, 22] or metachronous 
[15, 16, 20, 23] appearance of AIP and pancreatic cancer. At present, the only effect 
of the reports on the association between AIP and pancreatic cancer is to add a new 
problem to the differential diagnosis between AIP and pancreatic cancer. Even if 
several guidelines suggest that steroid treatment may help in arriving at a diagnosis of 
AIP [24], our current policy is to initiate the treatment only after an accurate diagnosis 
of AIP has been reached by means of biopsy pathology [13]. Caution should be taken 
regarding the possible presence of an adenocarcinoma in an inflammatory pancreatic 
mass based solely on the results of a pancreatic biopsy [25]. On the other hand, the 
serum determination of tumoral markers does not add any useful information because 
they may also be abnormally high in patients with AIP without the presence of a 
pancreatic adenocarcinoma [26]; neither does 18 FDG-PET help in diagnosing the 
simultaneous presence of pancreatic adenocarcinoma and AIP in the case of the absence 
of concomitant extrapancreatic uptake by the salivary glands or kidneys [27, 28]. Finally, 
it is also possible that AIP may be associated with biliary malignancies [29]; thus, 
additional larger case studies are needed to clarify the association of synchronous or 
metachronous pancreatobiliary malignancies with AIP. In conclusion, the 
recommendations of Kawa et al. [30] should be kept in mind; we must carefully monitor 
AIP patients for the simultaneous presence of pancreatic cancer, even when a diagnosis of 
AIP is confirmed. Case Rep Gastroenterol 2011;5:378–385 
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Fig. 1. CT scan. This examination was carried out after a double bypass biliary-enteric and 
gastro-enteric bypass for jaundice and unresectable head pancreatic mass and it shows a pancreatic 
mass (arrow) without dilation of the Wirsung duct. 
 
 
 
Fig. 2. Ultrasound-guided fine needle pancreatic biopsy (July 2010). The pathological examination 
reveals lymphoplasmacytic infiltrate (asterisks) (a) and granulocytic epithelial lesions (arrow) (b). 
 
 Case Rep Gastroenterol 2011;5:378–385 
DOI: 10.1159/000330291 
Published online: 
July 9, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–0631 
www.karger.com/crg   
 
 
 
382
 
Fig. 3. 18 FDG-PET. a CT image (CT coronals). b Positron emission tomography acquisition (PET 
coronals) shows a markedly increased glucose uptake in the mass of the pancreas head (SUV 6.1) 
(arrow). c Fusion image of CT and PET (fused coronals); the arrow indicates the pancreatic head mass. 
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Fig. 4. CT scan carried out in October 2010. This examination shows the pancreatic mass (asterisk) 
and the dilation of the main pancreatic duct behind the lesion (arrows). 
 
 
 
Fig. 5. Ultrasound-guided fine needle pancreatic biopsy (October 2010). The pathological examination 
shows the presence of a poor periductal lymphoplasmacytic infiltrate (white asterisk) and marked 
fibrosis (black asterisk) and the presence of both intraductal papillary mucinous neoplasia (black 
arrow) and ductal adenocarcinoma (white arrows). 
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